Featured
Health Topics
Any Category-
See more
- Amino Acids, Peptides, and Proteins 58
- Biological Factors 16
- Biomedical and Dental Materials 1
- Carbohydrates 10
- Chemical Actions and Uses 39
- Complex Mixtures 20
- Enzymes and Coenzymes 4
- Heterocyclic Compounds 67
- Hormones, Hormone Substitutes, and Hormone Antagonists 18
- Inorganic Chemicals 33
- Lipids 4
- Macromolecular Substances 1
- Nucleic Acids, Nucleotides, and Nucleosides 5
- Organic Chemicals 104
- Pharmaceutical Preparations 6
- Polycyclic Compounds 33
Search Clinical Trials
Completed
Protracted Etoposide During Induction Therapy for High Risk Neuroblastoma (External Link)
Induction Phase Overview The induction phase is approximately 15 weeks long. Chemotherapy is generally given every 3 weeks, each 3 week block is called a "cycle". During these 15 weeks …
Baylor Role:
Lead Sponsor
Completed
Karenitecin in Pediatric Patients With Refractory or Recurrent Solid Tumors N10010) (External Link)
This is a Phase 1, open-label, dose-escalating study of karenitecin plus cyclophosphamide in the treatment of pediatric patients with refractory or recurrent solid tumors. All patients must have histologically documented …
Baylor Role:
Lead Sponsor
Completed
Oral Nadolol for the Treatment of Adults With Mild Asthma (External Link)
The purpose of this study is to confirm previous observations in asthmatics that chronic nadolol treatment reduces asthmatic airway hyper-responsiveness.
Baylor Role:
Collaborator
Completed
Research Study for Children With Salt Wasting Congenital Adrenal Hyperplasia (External Link)
The adrenal gland is a small organ of the body. It produces very important chemicals called hormones. One of these hormones, cortisol (the stress hormone) helps the body fight diseases. …
Baylor Role:
Lead Sponsor
Completed
Selegiline to Zelapar Switch Study in Parkinson Disease Patients (External Link)
This is an open label, multicenter, 6 week study of the conversion from oral selegiline to orally disintegrating selegiline in PD patients with or without motor fluctuations, and currently taking …
Baylor Role:
Lead Sponsor
Completed
Tamoxifen for Progressive Transitional Cell Carcinoma Following Previous Chemotherapy Treatment (External Link)
The major objective of this two-stage phase II study is to determine whether tamoxifen is deserving of further study in metastatic bladder cancer. Tamoxifen is expected to function as a …
Completed
Research Study for Major Depressive Disorder: Investigation of Glutamate Medications (External Link)
This research proposal will investigate a glutamate-modulating agent, riluzole, in treatment-resistant patients who exhibit an acute, sustained response to a single dose of intravenous (IV) racemic ketamine. Fifty ketamine-responders will …
Baylor Role:
Lead Sponsor
Completed
Treatment of B-Chronic Lymphocytic Leukemia (B-CLL) With Autologous CD40 Ligand and IL-2-Expressing Tumor Cells (External Link)
Previously, some of the cancer cells taken from the patients body were separated in the laboratory and a specially produced human virus (adenovirus) that carries the IL-2 gene was put …
Baylor Role:
Lead Sponsor
Completed
Effectiveness of Tropisetron Plus Risperidone for Improving Cognitive and Perceptual Disturbances in Schizophrenia (External Link)
Schizophrenia is a chronic and disabling brain disorder. People with schizophrenia may experience hallucinations, delusions, disordered thinking, movement disorders, social withdrawal, and cognitive deficits. In considering the high rate of …
Baylor Role:
Lead Sponsor
Completed
Parcopa Versus Carbidopa-levodopa in a Single Dose Cross-over Comparison Study (External Link)
This is a study to compare orally dissolving levodopa (Parcopa) to the conventional immediate release oral levodopa. This is a single-dose, double-blind, placebo controlled crossover trial in participants with Parkinson …
Baylor Role:
Lead Sponsor